Background: Oral tongue squamous cell carcinoma (SCC) is characterized by early metastasis and poor prognosis. Interleukin-17F (IL-17F) plays a protective role in many tumors. However, IL-17F expression in oral tongue SCC tissue has not been investigated.
| I NT ROD UCTI ON
Oral tongue squamous cell carcinoma (SCC) is the most common type of oral cancer worldwide and accounts for more than half of the malignant lesions in the oral cavity. 1, 2 The incidence rate of oral tongue SCC has increased recently. This increase is linked to several factors, including increased consumption of alcohol and tobacco products. [3] [4] [5] Despite improved treatment approaches, oral tongue SCC therapy remains challenging because of rapid local invasion and early metastasis of the tumor cells to regional lymph nodes. 6 Interleukin-17F (IL-17F) is the most recently characterized member of the IL-17 cytokine family. This family includes 6 IL-17 cytokines, namely, IL-17A through F. Of all IL-17 members, IL-17F shares the greatest homology with IL-17A. 7 Unlike IL-17A, which is known as a protumorigenic cytokine, IL-17F was shown to have an antitumorigenic effect in several cancer types through different mechanisms. 8, 9 In colon cancer, IL-17F was reported as an inhibitory molecule of tumor angiogenesis; we also showed that IL-17F levels were significantly lower than those in nonmalignant control samples. 10, 11 Moreover, IL-17F inhibits the proliferation of hematopoietic malignant cells, such as mastocytoma and plasmocytoma. 12 In addition, IL-17F provides a protective effect against hepatocellular carcinoma through the inhibition of tumor angiogenesis. 13 Interestingly, IL-17F levels were lower in the serum of patients with oral cancer than in the serum of patients with leukoplakia and healthy controls. 14 Altogether, such reports apparently suggest an inverse relationship between IL-17F and tumorigenesis. However, local IL-17F expression and its putative role in oral tongue SCC remain unknown. In this study, we evaluated the cellular sources of IL-17F in oral tongue SCC tissue sections and investigated its possible association with patients' prognosis and mortality.
| MA TERI A LS AND M ETH ODS
This study was performed according to the REMARK guidelines for tumor marker prognostic studies. 
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| Patients
| Immunohistochemical staining
Paraffin-embedded samples were cut into 5-lm-thick sections using Leica RM2255 microtome (Leica Microsystems, Wetzlar, Germany). Immunohistochemical staining was performed using the Goat on Rodent HRP-polymer kit (Biocare Medical, Pacheco, CA). After deparaffinization, antigens were retrieved in citrate buffer (Dako, Carpinteria, CA) for 15 minutes using a microwave and followed by 20-minute cooling at room temperature. Endogenous peroxidase activity was blocked with Dako Peroxidase blocking solution for 15 minutes. Polyclonal goat antihuman IL-17F primary antibody (R&D Systems, Minneapolis, MN) at a concentration of 1 lg/mL was applied first for 30 minutes at 378C then overnight at 48C. On the following day, goat probe was applied for 15 minutes and followed by Goat on Rodent HRP- 
| Immunofluorescence staining
After deparaffinization, antigen retrieval was performed using a microwave oven (MicroMED T=T Mega Histoprocessing Labstation; Milestone Srl, Sorisole, Italy). Slides were then treated with 0.5% triton X-100 for 10 minutes at room temperature. Slides were washed 3 times (5 minutes each wash) in phosphate-buffered saline (PBS) and incubated in 10% normal serum for 1 hour. Serum was subsequently blotted away and slides were incubated overnight at 48C in primary antibodies (detailed antibody information is listed in Table 2 ). Slides were washed 3 times (5 minutes each wash) in PBS and incubated in fluorescein-conjugated secondary antibodies (Alexa Fluor, Molecular Probes, Leiden, The Netherlands) for 1 hour at room temperature. After 3 washes (5 minutes each wash) in PBS, nuclei were counterstained with 4 0 ,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich)
for 10 minutes at room temperature. Slides were mounted in Vectashield mounting medium (Vector Laboratories, Burlingame, CA). The specificity of each staining was confirmed with staining controls. 
| Assessment of interleukin-17F expression
Two independent researchers (R.A. and M.S.) analyzed IL-17F staining; both researchers were blinded to the clinical data. The scoring criteria are listed in Table 3 . Inflammatory cell distribution was scored in the tumor area and in the invasion front (Figure 1 ). The number of IL-17F-positive mast cells in the tumor area and invasion front was counted from 3 randomly selected 203 magnification fields per slide.
| Imaging of stained specimens
A fully automated Leica DM6000 microscope together with Leica DFC365-FX camera (Leica Microsystems) and a BX61 Motorized System Microscope (Olympus Life and Material Science Europa GmbH, Hamburg, Germany) were used to image the immunostained slides. Representative figures are presented in the Results section. Table 4 ). Inflammatory cells showed sporadically strong IL-17F expression ( Figure 2D ). The IL-17F staining in the cells that have mast cell morphology was either in the cytoplasm (intracellular) or extracellular ( Figure 2E ). Double immunofluorescence staining using IL-17F and mast cell tryptase antibodies confirmed the 2 patterns of the staining ( Figure 2F ,G). Staining with both inflammatory cell markers and IL-17F demonstrated that the majority of mast cells were positive for IL-17F ( Figure 3A) and only a few were negative ( Figure 3B ). Some CD4-positive T helper cells exhibited weak IL-17F immunoreactivity ( Figure 3C ). On the other hand, CD20-positive B cells, CD8-positive T cells, and CD163-positive macrophages were negative for IL-17F (data not shown).
| Statistical analysis
| Mast cells positive for interleukin-17F
are more common at the invasion front in oral tongue squamous cell carcinoma
Mast cells positive for IL-17F were often seen in the invasion front (60.2%; Figure 4A ; Table 4 ). Other inflammatory cells positive for IL-17F were more commonly located in the tumor area (80.7%; Figure 4B ; Table 4 ) and to a lesser extent in the invasion front (39.8%; Table 4 ). The IL-17F-positive mast cell count was higher in the invasion front compared to the tumor area (P < .0001; Figure 4C ).
| Extracellular mast cell interleukin-17F expression is predominant in oral tongue squamous cell carcinoma
Extracellular IL-17F from mast cells was predominant in 65.1% of patients at the invasion front and 74.7% of patients at the tumor areas (Table 4) . Additionally, extracellular IL-17F from mast cells represented 57.4% of the total IL-17F-positive mast cells at the tumor area and 59.9% at the invasion front ( Figure 4D ).
| Extracellular interleukin-17F from the invasion-front mast cells predicts the survival outcome of patients with oral tongue squamous cell carcinoma
We applied univariate analyses for the mast cell extracellular IL-17F on cancer-specific deaths. Patients with extracellular IL-17F in the invasion front had longer disease-specific survival (DSS) compared with patients with intracellular IL-17F expression. This was shown in all stages (HR 3.79, 95% confidence interval [CI] 1.64-8.80, P 5 .001; Figure 5A , Table  5 ), in patients with early-stage (HR 4.99, 95% CI 1.28-19.38, P 5 .01; Figure 5B , Table 6 ) and late-stage (HR 3.34, 95% CI 1.11-10.06, P 5 .03; Figure 5C , 
| DI S CU S S IO N
Although IL-17F-mediated immunity is considered as a crucial host defense mechanism against infections, IL-17F is now believed to play a pivotal role in tumorigenesis. [10] [11] [12] [13] [14] In the present study, we showed for the first time that the extracellular localization of IL-17F from mast cells at the invasion front is associated with improved overall survival and prognostic outcomes for patients with oral tongue SCC. Cancer cells produce various cytokines and chemokines that recruit immune cells to the tumor site. Indeed, the inflammatory component of the tumor microenvironment includes a wide range of inflammatory cells, including neutrophils, macrophages, lymphocytes, and mast cells. These cells can synthesize and produce a large amount of cytokines and cytotoxic mediators. 16, 17 Among these cells, mast cells are regarded as highly important components of the tumor microenvironment and are involved in orchestrating immune responses against the tumor cells. 18 Furthermore, we showed in a recent study that mast cell count was noticeably increased in specimens of patients with oral tongue SCC compared with those retrieved from patients with oral dysplasia and normal controls. 19 In this context, it is interesting to find that IL-17F immunoreactivity was most intense in mast cells compared with the other inflammatory infiltrate cells, such as lymphocytes. This finding suggests that mast cells are the major cellular source of IL-17F in patients with oral tongue SCC, which is consistent with other reports that highlighted mast cells (as opposed to T cells) as the main producers of IL-17F in human dermal tissue. 20 Inflammatory cell distribution and interaction in tissues are considered as significant features in interpreting the therapeutic outcomes of many tumors. 16, 21 We recently observed such an interaction between cancer and inflammatory cells in a 3D human-derived in vitro model that demonstrated the ability of inflammatory cells to influence cancer cell proliferation and invasion. 22 Furthermore, our group previously found a significant correlation between inflammatory cell infiltrates and oral tongue SCC recurrence. 23 In particular,
we reported that patients with samples rich in CD163-positive cells, Foxp3-positive regulatory T cells, and CD80-positive cells showed higher incidence of cancer recurrence than in patients with a lower abundance of such cells. 23 However, our findings in the present study suggest a nonsignificant correlation between the morphometrical distribution of the total inflammatory cells and the clinical status of patients with all-stages of oral tongue SCC. Mast cells produce a large variety of effector molecules. These molecules are released extracellularly either within minutes of activation (acute phase of disease) or over hours or even days (delayed or chronic phase). 18 Despite the controversial role of mast cells in carcinogenesis, several studies have reported that mast cells play a protective role in human cancers and improve prognosis, such as in colorectal and oral cancers. [24] [25] [26] As for oral tongue cancer, the mast cell count showed significant correlation with the tumor stage but not tumor grade or lymph node metastasis. 27 Here, we report that extracellular IL-17F from mast cells at the invasion front was significantly associated with improved overall prognosis of patients with oral tongue SCC. This result is supported by the fact that intracellular IL-17F is most probably nonfunctional because of the lack of any known intracellular IL-17F receptors and, thus, cannot initiate ligand-receptor responses. 28, 29 Similar phenomena are also known for other inflammatory molecules, such as histamine. Histamine remains inactive inside the granules of mast cells until its release upon degranulation to the oral mucosal environment. 30 In conclusion, extracellular mast cell-derived IL-17F has a protective role in oral tongue SCC. It also could separate high-risk from low-risk patients with early-stage oral tongue SCC. Furthermore, we have also demonstrated the importance of the cellular source, distribution, and localization criteria in the histopathological evaluation of tentative molecular biomarkers. Unfortunately, the vast majority of biomarker studies still only evaluate the molecular expression intensity in the cancer cells; even when the tumor microenvironment is counted, only staining intensity is evaluated. Such criteria of the studied molecules should be taken into consideration before implementing their use in routine clinical practice. There are, however, some limitations in our study, such as the use of a semiquantitative immunohistological assessment and the lack of functional IL-17F experiments; performance of such experiments is warranted in the future.
